...

首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >National Lung Matrix Trial: multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer

【24h】

National Lung Matrix Trial: multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer

机译：全国肺基质试验：针对非小细胞肺癌的多药，遗传标记指导，非比较，多中心，多组II期临床试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Lung cancer: Journal of the International Association for the Study of Lung Cancer》 |2015年第1期|共2页
作者
Middleton G.; Billingham L.; Crack L.; Popat S.; Walker I.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. National Lung Matrix Trial: multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer [J] . Middleton G., Billingham L., Crack L., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2015,第Suppla1期

机译：全国肺基质试验：针对非小细胞肺癌的多药，遗传标记指导，非比较，多中心，多组II期临床试验
2. Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902 [J] . Kanazawa Kenya, Yokouchi Hiroshi, Wang Xintao, Cancer chemotherapy and pharmacology. . 2014,第6期

机译：卡铂和培美曲塞作为一线化疗治疗非鳞状非小细胞肺癌的第二阶段试验，以及与培美曲塞代谢相关的功效/毒性和遗传多态性之间的相关性：北海道肺癌临床研究组试验（HOT）0902
3. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC) [J] . Roger B. Cohen, Corey J. Langer, George Rajan Simon, Cancer Chemotherapy and Pharmacology . 2007,第1期

机译：CP-547,632联合紫杉醇和卡铂或单独使用紫杉醇和卡铂作为晚期非小细胞肺癌（NSCLC）的一线治疗的I期/随机II期，非比较，多中心，开放标签试验
4. A Deep Learning-Facilitated Radiomics Solution for the Prediction of Lung Lesion Shrinkage in Non-Small Cell Lung Cancer Trials [C] . Antong Chen, Jennifer Saouaf, Bo Zhou, IEEE International Symposium on Biomedical Imaging . 2020

机译：在非小细胞肺癌试验中用于预测肺病变萎缩的深度学习促进放射组学解决方案
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. A multi-centre randomized open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer [O] . M. MICHAEL, N. PAVLAKIS, P. CLINGAN, -1

机译：连续厄洛替尼联合吉西他滨或吉西他滨作为一线治疗在ECOG PS2晚期非小细胞肺癌患者中的多中心随机开放试验II期试验
7. PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC) [O] . G. Middleton, S. Popat, P. Fletcher, 2019

机译：PL02.09国家肺基质试验（NLMT）：先进的非小细胞肺癌（NSCLC）中的伞形二期试验中的首先结果

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号